Inventor · disambiguated record
Hamid R. Hoveyda
Also filed as: HOVEYDA HAMID · HOVEYDA HAMID R · HOVEYDA HAMID REZA
54 granted patents·16 pending applications·406 citations·filing 1991–2023
98Inventor score
Top patents by PatentIndex Score
70 records- 0195US9422299B2Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsEUROSCREEN SA·Filed 2015·Granted Aug 23, 2016·17 cites·30 claims
- 0295US7491695B2Methods of using macrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2005·Granted Feb 17, 2009·39 cites·18 claims
- 0395US7476653B2Macrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2005·Granted Jan 13, 2009·48 cites·14 claims
- 0494USRE42624EMethods of using macrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2009·Granted Aug 16, 2011·17 cites·18 claims
- 0594US7521420B2Macrocyclic antagonists of the motilin receptorTRANZYME PHARMA INC·Filed 2004·Granted Apr 21, 2009·46 cites·12 claims
- 0693US8129561B2Processes for intermediates for macrocyclic compoundsMARSAULT ERIC·Filed 2008·Granted Mar 6, 2012·15 cites·28 claims
- 0792US8088733B2Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disordersFRASER GRAEME L·Filed 2007·Granted Jan 3, 2012·22 cites·16 claims
- 0892USRE42013EMacrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2009·Granted Dec 28, 2010·18 cites·14 claims
- 0991US8871761B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersEUROSCREEN SA·Filed 2012·Granted Oct 28, 2014·15 cites·12 claims
- 1089US8349887B2Methods of treating cachexia with macrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2011·Granted Jan 8, 2013·11 cites·6 claims
- 1187US8450268B2Methods of using macrocyclic modulators of the ghrelin receptorFRASER GRAEME L·Filed 2008·Granted May 28, 2013·10 cites·8 claims
- 1285US9987274B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2016·Granted Jun 5, 2018·4 cites·19 claims
- 1385US7452862B2Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonistsTRANZYME PHARMA INC·Filed 2004·Granted Nov 18, 2008·23 cites·4 claims
- 1484US11478472B2NK-3 receptor antagonists for therapeutic treatment of leptin-related diseaseOGEDA SA·Filed 2020·Granted Oct 25, 2022·1 cites·8 claims
- 1584US10787458B2Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazinesOGEDA SA·Filed 2019·Granted Sep 29, 2020·2 cites·14 claims
- 1683US9475814B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofEUROSCREEN SA·Filed 2012·Granted Oct 25, 2016·7 cites·20 claims
- 1782US10836768B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2018·Granted Nov 17, 2020·1 cites·12 claims
- 1882US2024199618A1NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERSOGEDA SA·Filed 2023·Application pending·0 cites
- 1981US10183948B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2017·Granted Jan 22, 2019·1 cites·13 claims
- 2081US7550431B2Spatially-defined macrocycles incorporating peptide bond surrogatesTRANZYME PHARMA INC·Filed 2004·Granted Jun 23, 2009·16 cites·3 claims
- 2180US10624890B2NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fatOGEDA SA·Filed 2016·Granted Apr 21, 2020·2 cites·10 claims
- 2280US8022252B2Spatially-defined macrocyclic compounds useful for drug discoveryTRANZYME PHARMA INC·Filed 2008·Granted Sep 20, 2011·4 cites·3 claims
- 2379US9969745B2N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disordersOGEDA SA·Filed 2017·Granted May 15, 2018·2 cites·11 claims
- 2478US12458641B2NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fatOGEDA SA·Filed 2022·Granted Nov 4, 2025·0 cites·4 claims
- 2577US10065961B2Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofEUROSCREEN SA·Filed 2016·Granted Sep 4, 2018·2 cites·5 claims
- 2676US9969738B2N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disordersEUROSCREEN SA·Filed 2014·Granted May 15, 2018·2 cites·9 claims
- 2775US11078203B2Deuterated fezolinetantOGEDA SA·Filed 2018·Granted Aug 3, 2021·1 cites·9 claims
- 2874US10683295B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofOGEDA SA·Filed 2018·Granted Jun 16, 2020·1 cites·5 claims
- 2974US8440851B2Spatially-defined macrocyclic compounds useful for drug discoveryMARSAULT ERIC·Filed 2011·Granted May 14, 2013·2 cites·5 claims
- 3073US11731974B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2020·Granted Aug 22, 2023·0 cites·8 claims
- 3173US10030025B2Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsEUROSCREEN SA·Filed 2016·Granted Jul 24, 2018·1 cites·19 claims
- 3272US5300496AComplexed vanadium for the treatment of diabetes mellitusUNIV BRITISH COLUMBIA·Filed 1991·Granted Apr 5, 1994·41 cites·6 claims
- 3370US5620967AMethods of treating hypertension with vanadium compositionsUNIV BRITISH COLUMBIA·Filed 1995·Granted Apr 15, 1997·26 cites·5 claims
- 3468US11072582B2Substituted pyrrolidines as G-protein coupled receptor 43 agonistsEPICS THERAPEUTICS·Filed 2020·Granted Jul 27, 2021·0 cites·25 claims
- 3568US10781171B2Substituted pyrrolidines as G-protein coupled receptor 43 agonistsEPICS THERAPEUTICS·Filed 2020·Granted Sep 22, 2020·0 cites·1 claims
- 3667US10941151B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofOGEDA SA·Filed 2020·Granted Mar 9, 2021·0 cites·4 claims
- 3767US10577318B2Substituted pyrrolidines as G-protein coupled receptor 43 agonistsEPICS THERAPEUTICS·Filed 2019·Granted Mar 3, 2020·0 cites·1 claims
- 3866US9181298B2Intermediates for macrocyclic compoundsMARSAULT ERIC·Filed 2008·Granted Nov 10, 2015·0 cites·3 claims
- 3964US9695120B2Substituted pyrrolidines as G-protein coupled receptor 43 agonistsHOVEYDA HAMID R·Filed 2012·Granted Jul 4, 2017·1 cites·36 claims
- 4064US2020125564A1Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disordersOGEDA SA·Filed 2019·Application pending·0 cites
- 4162US10358416B2Substituted pyrrolidines as G-protein coupled receptor 43 agonistsOGEDA SA·Filed 2018·Granted Jul 23, 2019·0 cites·2 claims
- 4262US10258602B2Macrocyclic ghrelin receptor modulators and methods of using the sameOCERA THERAPEUTICS INC·Filed 2018·Granted Apr 16, 2019·0 cites·16 claims
- 4361US9926325B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2014·Granted Mar 27, 2018·0 cites·4 claims
- 4461US2012165566A1Processes for intermediates for macrocyclic compoundsMARSAULT ERIC·Filed 2012·Application pending·0 cites
- 4561US2012226072A1Processes for intermediates for macrocyclic compoundsMARSAULT ERIC·Filed 2012·Application pending·0 cites
- 4661US2012226066A1Processes for intermediates for macrocyclic compoundsMARSAULT ERIC·Filed 2012·Application pending·0 cites
- 4761US2012226067A1Processes for intermediates for macrocyclic compoundsMARSAULT ERIC·Filed 2012·Application pending·0 cites
- 4860US10040751B2Intermediates for macrocyclic compoundsOCERA THERAPEUTICS INC·Filed 2015·Granted Aug 7, 2018·0 cites·21 claims
- 4959US10544150B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2018·Granted Jan 28, 2020·0 cites·12 claims
- 5059US10017468B2Substituted pyrrolidines as G-protein coupled receptor 43 agonistsOGEDA SA·Filed 2017·Granted Jul 10, 2018·0 cites·3 claims
Showing the top 50 of 70 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →